In Clinics in laboratory medicine ; h5-index 28.0
Advancements in technology have improved biomarker discovery in the field of heart failure (HF). What was once a slow and laborious process has gained efficiency through use of high-throughput omics platforms to phenotype HF at the level of genes, transcripts, proteins, and metabolites. Furthermore, improvements in artificial intelligence (AI) have made the interpretation of large omics data sets easier and improved analysis. Use of omics and AI in biomarker discovery can aid clinicians by identifying markers of risk for developing HF, monitoring care, determining prognosis, and developing druggable targets. Combined, AI has the power to improve HF patient care.
Michelhaugh Sam A, Januzzi James L
2023-Mar
Artificial intelligence, Biomarkers, Genomics, Heart failure, Metabolomics, Proteomics, Transcriptomics
